Biorbis Antibody Engineering and Design Conference and Workshops

Registration, Coffee and Networking

Chairman's opening remarks

Dr Zhenping Zhu
Vice President and Global Head, Protein Sciences
Novartis

UCB's Selected Lymphocyte Antibody Method (SLAM): Discovery of Superior Therapeutic Antibodies Through Efficient Sampling of Immune Repertoires

• A description of UCB's Selected Lymphocyte Antibody Method (SLAM)
• Highlight how SLAM enables efficient sampling of the immune repertoire in order to discover high quality antibodies
• Examples of how SLAM has been applied across a number of UCB therapeutic programs

Dr Daniel Lightwood
Senior Group Leader, Antibody Discovery
UCB-Celltech

Novel Platform Technology Producing Fully Human Monoclonal Antibodies

• In vitro production without phage display or transgenic animals
• Ability to generate highly-specific antibodies to any antigen
• Scalable system

Dr Ryan Fiorini, Chief Operating Officer, Immunologix

Morning refreshments

Antibody Affinity Maturation and Sequence Optimization

• A method that interweaves sequence optimization and affinity maturation is presented
• Comprehensive site-directed saturation mutagenesis and HTS are routinely applied
• The process is stable and universally applicable

Dr Ulrich Haupts, Director, Assay Technology and Analytics, Bayer

Impact of Library Quality on Antibody Affinity Maturation Outcome

• Alternative design and construction of affinity maturation libraries
• The Impact of phage rescue in library quality and diversity
• Reducing the impact of library quality by selection strategies
• Characterization of AFM candidates

Dr Horacio Nastri, Head, Antibody Technologies, EMD Serono

Challenges, Expectations and Insights into Antibody Species Cross-Reactivity

• Understanding the importance of species cross-reactivity
• Engineering species cross-reactivity into antibody candidates

Dr Tristan Vaughan
Senior Director, Lead Generation
MedImmune

Lunch

Case Study: Overview of Current Epitope Mapping Techniques Used for Biopharmaceutical Research

• Highlights on the use of H/D-exchange for epitope mapping
• Case study utilizing multiple techniques to determine an epitope with a focus on H/D-exchange

Dr Dariusz Janecki, Research Scientist, Biologics Mass Spectrometry, Centocor

Protein Engineering and Developmental Consideration of DVD-Ig as the Next Generation of Bispecific Biologics

• DVD-Ig as a promising bispecific biologic generation platform
• Meeting challenges in manufacturability and drug-like properties of bispecific antibodies
• Assessment of DVD-Ig in pharmacokinetics, preformulation solubility and stability, and CHO cell line development
• Lessons learned from DVD-Ig engineering and best practices
• Examples of DVD-Ig targeting different antigen classes

Dr Chung-Ming Hsieh
Senior Geroup Leader, Biologics Research
Abbott

Dr Jijie Gu, Principal Scientist, Biologics Research, Abbott

Afternoon Refreshments

Bispecific Antibodies: Pre-clinical Development of Dual-Targeting Agents for Oncology and Autoimmune Disease Indications

• Construction and characterization of Biogen Idec bispecific antibodies
• Example of a bispecific antibody targeting two receptors with potent activity in pre-clinical oncology models
• Example of a bispecific antibody targeting two ligands for autoimmune indications

Dr Jennifer Michaelson
Principal Scientist, Molecular Discovery
Biogen Idec

Multi-specific Adnectins: Developing a New Class of Targeted Biologics

• Adnectins demonstrate speed of discovery, efficient manufacturing and the ability to create multi-functional targeted products
• Developing Adnectin dimers to enable modulation of two distinct targets
• Preclinical data on a bispecific Adnectin to EGFR and IGF1R will be presented

Dr Linda Engle
Principal Scientist, Discovery
Adnexus (a BMS company)

Chairman's closing remarks